We aim to deliver innovative solutions, enhance healthcare access, and solidify our leadership in the pharmaceutical industry. Our strategic priorities focus on enhancing competitiveness and charting a course for sustained excellence. Further, we have accelerated our digitization initiatives to strengthen operational prudence, primarily addressing diverse functional and enterprise needs. Together, these efforts help us maintain growth momentum and achieve our objectives.
We diligently pursue cost optimization initiatives, to maintain financial prudence. Through strategic measures we ensure efficient resource allocation, bolstering financial stability and fostering sustainable growth.
Increment in EBITDA margin
Increment in gross margin
EPS growth
Improvement in ROCE
Our intensified focus on quality-driven product development has propelled us to establish our brands among the top 15 list of the IPM. These brands have garnered strong recall among customers, solidifying our market leadership. We are the leaders in the anti-infective market. Further, in 2023, we launched world’s first biosimilar of Cetuximab, namely Cetuxa. Collectively, these achievements underscore our prowess in commercial execution and position us as a trusted entity among customers.
Moving towards
Brands among the top-15 brands in the IPM
Growth in antidiabetic portfolio which outperformed the market growth of 6%
Led by lower raw material cost and improved product mix
Maintained in represented market
Our strategic focus on the Rest of the World (ROW) markets stems from their pivotal role in driving robust business performance. With notable upticks in off-take and EBITDA margins, our aim is to intensify our presence in these markets. By enhancing penetration with greater product portfolio, we anticipate sustained growth and improved profitability, further fortifying our momentum.
Marks the primary presence of the Company in ROW markets
Registered across major markets like Chile, UK, and Germany
Sales registered
Contribution to total sales
We are strengthening our digital footprint through enhanced IT infrastructure. The aim is to bolster our competitive edge and delineate our revamped organizational identity. Through a robust digital infrastructure, we intend to streamline operations while enhancing productivity.
Our India business generates the greater share of revenue with 67.8% share. We are primarily active in the acute and chronic therapies where we hold a leadership position in the acute therapies specially in the gastro-intestinal, anti-infective, VMN segment. Our acute therapy portfolio includes flagship brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst the top 50 pharmaceutical brands in India. Additionally, we have attained robust performance among the chronic therapies where anti-diabetic, and derma segment has outperformed IPM growth simultaneously during the reporting period.
in Anti diabetic, Derma, GI VMN therapies
in Anti diabetic, cardiac and respiratory therapies
Year-on-year sales improvement
We are intensifying our Contract Development and Manufacturing Organization (CDMO) business through our subsidiary Enzene. Seven successful product launches and promising market projections underpin our expansion strategy. We are bolstering our portfolio and venturing into the US market with a new manufacturing plant.
Menu
Get a comprehensive view of our financial performance